Beijing Sun-Novo Pharmaceutical Research Co., Ltd., commonly referred to as Sun-Novo, is a leading player in the pharmaceutical industry, headquartered in Beijing, China. Established in 2003, the company has made significant strides in drug discovery and development, focusing on innovative solutions for various therapeutic areas, including oncology and cardiovascular diseases. With a strong presence in both domestic and international markets, Sun-Novo is renowned for its commitment to research and development, offering a diverse portfolio of core products and services. Their unique approach combines advanced technology with a deep understanding of patient needs, positioning them as a trusted partner in the pharmaceutical landscape. Notable achievements include successful collaborations and a growing pipeline of novel therapeutics, solidifying Sun-Novo's reputation as a key contributor to global health advancements.
How does Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s score of 22 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments towards reducing its carbon footprint. As there are no emissions data or reduction initiatives available, it is unclear how Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is addressing climate change within the pharmaceutical industry context. The absence of emissions reporting may reflect a broader trend in the sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets in line with global climate goals. In summary, without specific emissions data or reduction commitments, it is challenging to assess Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s climate performance or its alignment with industry standards for sustainability.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.